HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced cancers? XL092 combo enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New drug GTAEXS617 enters human trials for tough cancers
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New drug STRO-004 enters human trials for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Experimental combo aims to tackle returning head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether giving a second round of radiation together with a drug called chidamide is safe for people whose head and neck cancer has come back after previous radiation. Only 6 participants will be enrolled to find the best dose and check for side effect…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New drug EPI-326 enters human testing for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug duo aims to shrink head and neck tumors in first-line treatment
Disease control Recruiting nowThis study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with head and neck cancer that has come back or spread. About 120 adults whose tumors have a specific protein (PD-L1) wil…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new experimental drug (LB-LR1109) in people with advanced solid tumors like lung, kidney, or skin cancer that no longer respond to standard treatments. The study has two parts: first, the drug is given alone to find the safest dose; second, it is co…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug duo shows promise in shrinking head and neck tumors before surgery
Disease control Recruiting nowThis study tests whether giving two drugs—ficerafusp alfa and pembrolizumab—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 adults with a specific type of this cancer will receive the combination, then have surgery. The goal is to see if th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Can Six-Day radiation beat Five-Day for head and neck cancer?
Disease control Recruiting nowThis study compares two radiation schedules for people with head and neck cancer who start treatment more than six weeks after surgery. One group gets radiation six days a week (accelerated), the other gets the standard five days a week. The goal is to see if the faster schedule …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs (GV20-0251 and sintilimab) before surgery is safe and can shrink tumors in adults with advanced head and neck cancer. Nine participants will receive two cycles of the drug combo, then undergo surgery. The study focuses on s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Could less radiation be just as effective for head and neck cancer patients?
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a complete response to chemo-immunotherapy before neck surgery can safely receive less radiation afterward. The goal is to keep cancer from coming back while improving quality of life. About 50 particip…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
App-Based monitoring may prevent weight loss in head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether using a smartphone app to regularly report symptoms can help doctors catch problems early and reduce weight loss in patients receiving radiation for head and neck cancer. About 192 adults will be followed for 3 months after treatment. The goal is to see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated May 11, 2026 20:48 UTC
-
New study gathers key materials for Next-Gen cancer therapy
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC